AR107027A1 - COMPLEMENTARY ACTIVITY MODULATORS - Google Patents
COMPLEMENTARY ACTIVITY MODULATORSInfo
- Publication number
- AR107027A1 AR107027A1 ARP160103773A ARP160103773A AR107027A1 AR 107027 A1 AR107027 A1 AR 107027A1 AR P160103773 A ARP160103773 A AR P160103773A AR P160103773 A ARP160103773 A AR P160103773A AR 107027 A1 AR107027 A1 AR 107027A1
- Authority
- AR
- Argentina
- Prior art keywords
- modulators
- complementary activity
- concentration
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Moduladores polipeptídicos de actividad complementaria que incluyen moduladores polipeptídicos cíclicos de actividad complementaria. Métodos para utilizar dichos moduladores como agentes terapéuticos. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende R5000 y un excipiente farmacéuticamente aceptable, donde el excipiente farmacéuticamente aceptable comprende cloruro de sodio en una concentración de entre aproximadamente 25 mM y aproximadamente 100 mM y fosfato de sodio en una concentración de entre aproximadamente 10 mM y aproximadamente 100 mM. Reivindicación 7: Un método para inhibir la hemólisis en un sujeto, caracterizado porque comprende administrar una composición farmacéutica de cualquiera de las reivindicaciones 1 - 6.Complementary activity polypeptide modulators that include complementary cyclic polypeptide modulators. Methods for using such modulators as therapeutic agents. Claim 1: A pharmaceutical composition characterized in that it comprises R5000 and a pharmaceutically acceptable excipient, wherein the pharmaceutically acceptable excipient comprises sodium chloride in a concentration of between about 25 mM and about 100 mM and sodium phosphate in a concentration of between about 10 mM and approximately 100 mM. Claim 7: A method of inhibiting hemolysis in a subject, characterized in that it comprises administering a pharmaceutical composition of any one of claims 1-6.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562268360P | 2015-12-16 | 2015-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR107027A1 true AR107027A1 (en) | 2018-03-14 |
Family
ID=61768583
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160103773A AR107027A1 (en) | 2015-12-16 | 2016-12-07 | COMPLEMENTARY ACTIVITY MODULATORS |
ARP210100437A AR121381A2 (en) | 2015-12-16 | 2021-02-19 | PHARMACEUTICAL COMPOSITION INCLUDING MODULATORS OF COMPLEMENTARY ACTIVITY AND AUTOINJECTOR DEVICE |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100437A AR121381A2 (en) | 2015-12-16 | 2021-02-19 | PHARMACEUTICAL COMPOSITION INCLUDING MODULATORS OF COMPLEMENTARY ACTIVITY AND AUTOINJECTOR DEVICE |
Country Status (1)
Country | Link |
---|---|
AR (2) | AR107027A1 (en) |
-
2016
- 2016-12-07 AR ARP160103773A patent/AR107027A1/en unknown
-
2021
- 2021-02-19 AR ARP210100437A patent/AR121381A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR121381A2 (en) | 2022-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2017000271A (en) | PATIENT CONDITIONING METHODS FOR T-LYMPHOCYT TREATMENT | |
DOP2017000272A (en) | METHODS OF DIAGNOSIS FOR TREATMENT WITH LYMPHOCYTES T | |
CL2015003442A1 (en) | Heterocyclic derivatives | |
AR107014A1 (en) | PHARMACEUTICAL FORMULATION WATER | |
SV2015005115A (en) | DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES | |
BR112015006828A8 (en) | compound, or a pharmaceutically acceptable salt thereof; pharmaceutical composition; use of the compound; and method for modulating the activity of an ire1 protein | |
MA38399A1 (en) | Formulation in tablet form, useful for treating acute heart failure and chronic heart failure | |
MY188139A (en) | Sodium channel modulators for the treatment of pain | |
AR105712A1 (en) | QUICK ACTION INSULIN COMPOSITIONS | |
MX2018013973A (en) | Methods of treating behavioral syndromes using pipradrol. | |
ECSP16084317A (en) | PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE | |
BR112018015367A2 (en) | nanofiber oromucosal carriers for therapeutic treatment | |
CL2015002835A1 (en) | New pyridine derivatives | |
MX2021002321A (en) | Novel methods. | |
EA201501054A1 (en) | TREATMENT OF MYOPATHIES AND NEURODEGENERATIVE DISEASES ASSOCIATED WITH THE PROTECTION OF PROTEINS BY PARENTAL INTRODUCTION OF TRAGOSE | |
AR111374A1 (en) | USE OF LIK066 IN PATIENTS WITH HEART FAILURE | |
UY34896A (en) | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE | |
EA201792571A1 (en) | THERAPEUTIC APPLICATION OF L-4-CHLOROKINURENIN | |
EA201692402A1 (en) | MEDICAL FORMS FOR LOCAL APPLICATION AND THEIR USE | |
CR20140075A (en) | THERAPEUTIC METHODS | |
EA201692111A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES | |
CL2016002318A1 (en) | Pharmaceutical composition in the form of a solution comprising a liquid carrier comprising water and between 20% and 95% of one or more alcohols and sildenafil citrate dissolved in said liquid carrier at a concentration of between 7 and 125 mg / ml; methods to obtain it; oral dosage form; oral dosage form; kits | |
EA201792314A1 (en) | PHARMACEUTICAL COMBINATION OF EVEROLIMUS AND DACTOLYSIB | |
BR112018068960A2 (en) | enalapril formulations | |
EA201891319A1 (en) | COMPOUNDS OF ALKYDYDYDROCHINOLINSULPHONAMIDE |